HUP0500997A2 - Chemically-modified human growth hormone conjugates - Google Patents

Chemically-modified human growth hormone conjugates

Info

Publication number
HUP0500997A2
HUP0500997A2 HU0500997A HUP0500997A HUP0500997A2 HU P0500997 A2 HUP0500997 A2 HU P0500997A2 HU 0500997 A HU0500997 A HU 0500997A HU P0500997 A HUP0500997 A HU P0500997A HU P0500997 A2 HUP0500997 A2 HU P0500997A2
Authority
HU
Hungary
Prior art keywords
chemically
growth hormone
human growth
modified human
hormone conjugates
Prior art date
Application number
HU0500997A
Other languages
Hungarian (hu)
Inventor
Rory F Finn
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of HUP0500997A2 publication Critical patent/HUP0500997A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HU0500997A 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates HUP0500997A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
HUP0500997A2 true HUP0500997A2 (en) 2007-11-28

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500997A HUP0500997A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20050044858A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA200700431A1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc Novel monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP3669887A1 (en) * 2002-01-18 2020-06-24 Biogen MA Inc. Polyalkylene polymer compounds and uses thereof
MXPA05002620A (en) 2002-09-09 2005-05-05 Nektar Therapeutics Al Corp Water-soluble polymer alkanals.
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
CN100580087C (en) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 Conjugation of peptides
ATE550041T1 (en) * 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
KR20070042567A (en) * 2004-08-31 2007-04-23 파마시아 앤드 업존 캄파니 엘엘씨 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
MX2007007580A (en) 2004-12-22 2007-12-11 Ambrx Inc Modified human growth hormone.
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
US8080391B2 (en) * 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
JP2008531482A (en) 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ Growth hormone with PEGylated C-terminus
JP2008538290A (en) 2005-04-18 2008-10-23 ノボ ノルディスク アクティーゼルスカブ IL-21 mutant
AU2006286486A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
CN104710503B (en) 2005-11-08 2023-04-25 Ambrx 公司 Promoters for modification of unnatural amino acids and unnatural amino acid polypeptides
SG170116A1 (en) 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN101495155A (en) 2006-07-07 2009-07-29 诺沃-诺迪斯克保健股份有限公司 New protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
JP2010507382A (en) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ IL-21 mutant
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
PL2272875T3 (en) 2008-04-03 2014-06-30 Biosteed Gene Expression Tech Co Ltd Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
JP5639585B2 (en) * 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション Peptide-polymer conjugate
MX2011000847A (en) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy.
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
US8492503B2 (en) * 2008-09-11 2013-07-23 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
CN102612376A (en) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 Growth hormones with prolonged in-vivo efficacy
WO2011073234A2 (en) 2009-12-15 2011-06-23 Ascendis Pharma As Growth hormone composition
CN103002918B (en) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 The growth hormone that in body, effect extends
MX338357B (en) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
EP2571896A4 (en) * 2010-05-17 2014-01-08 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
CA2964390A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
WO2016145388A1 (en) * 2015-03-11 2016-09-15 Nektar Therapeutics Conjugates of an il-7 moiety and an polymer
EP3351561A4 (en) 2015-09-18 2019-05-15 University of Miyazaki Long-acting adrenomedullin derivative
CN114539384B (en) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (en) * 1990-05-04 1998-05-01 American Cyanamid Co STABILIZATION OF SOMATOTROPINS AND OTHER PROTEINS BY MODIFICATION OF CYSTEINE WASTE.
EP0576589A4 (en) * 1991-03-18 1994-07-27 Enzon Inc Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ES2190388T3 (en) * 1995-09-21 2006-04-01 Genentech, Inc. VARIANTS OF HUMAN GROWTH HORMONE.
CN1269805A (en) * 1997-07-14 2000-10-11 博尔德生物技术公司 Derivatives of growth hormone and related proteins
BR0008759B1 (en) * 1999-01-14 2014-03-11 Bolder Biotechnology Inc Methods for the production of protein containing free cysteine residues
CZ300546B6 (en) * 1999-01-29 2009-06-10 Amgen, Inc. Physiologically active conjugate, composition and process for preparing thereof
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
IS7268A (en) 2004-05-17
GEP20063860B (en) 2006-06-26
PL374354A1 (en) 2005-10-17
JP2005525302A (en) 2005-08-25
KR20050044858A (en) 2005-05-13
MA27544A1 (en) 2005-10-03
CO5580794A2 (en) 2005-11-30
ZA200403907B (en) 2007-12-27
JP2006321808A (en) 2006-11-30
AP2004003050A0 (en) 2004-06-30
NO20042182L (en) 2004-08-11
KR20070072924A (en) 2007-07-06
CA2467731A1 (en) 2003-05-30
WO2003044056A3 (en) 2003-08-21
ECSP045114A (en) 2004-07-23
HRP20040448A2 (en) 2006-02-28
EA008505B1 (en) 2007-06-29
EP1453859A2 (en) 2004-09-08
MXPA04004809A (en) 2004-08-11
OA13063A (en) 2006-11-10
EA200700431A1 (en) 2008-02-28
BR0214451A (en) 2006-05-30
TNSN04090A1 (en) 2006-06-01
IL162031A0 (en) 2005-11-20
CN1608079A (en) 2005-04-20
WO2003044056A2 (en) 2003-05-30
AU2002356990A1 (en) 2003-06-10
RS53104A (en) 2006-10-27
EA200400565A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
IL162031A0 (en) Chemically-modified human growth hormone conjugates
AU2002342653A8 (en) Modified growth hormone
AU2003304235A1 (en) Chemically-modified human growth hormone conjugates
AU9175801A (en) Flexible implant
GB0100658D0 (en) Crystallisation - resistant aqueous growth hormone formulations
AU6606601A (en) Growth hormone secretagogues
HUP0402496A3 (en) Growth hormone fusion protein
IL147253A0 (en) Growth hormone formulations
AU2001272974A1 (en) Human receptors
GB2411404B (en) Biologically active peptide conjugates
GB0119665D0 (en) Conjugates
GB0319495D0 (en) An implant
HUP0402334A3 (en) Modified human growth hormone
EP1385556A4 (en) Gastrin-receptor-avid peptide conjugates
GB0106565D0 (en) Growth hormone treatment
AU2002343197A8 (en) Biologically active complex
EP1373299A4 (en) Connective tissue growth factor-2
GB0111277D0 (en) Gentle marker
AU2002364314A8 (en) Growth hormone agonist peptides and their uses
GB2382347B (en) Hemoglobin conjugates
AU2001263350A1 (en) Peptides that stimulate mycobacterial growth
GB0408136D0 (en) A human G protein coupled receptor
GB0127214D0 (en) Growth hormone variations in humans an their uses
AU145153S (en) Implant
AU143439S (en) Curved crop lifter

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees